{"id":"W2335344368","doi":"10.1097/ogx.0b013e3182877729","title":"Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer","year":2013,"lang":"en","type":"article","venue":"Obstetrical & Gynecological Survey","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"","keywords":"Docetaxel; Medicine; Capecitabine; Gemcitabine; Bevacizumab; Breast cancer; Oncology; Cyclophosphamide; Chemotherapy; Internal medicine; Doxorubicin; Cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005228459,0.0003004129,0.001773438,0.0003652047,0.0002457064,0.0003960727,0.0002308954,0.0005348876,0.003441659],"category_scores_gemma":[0.001231524,0.0002968773,0.0005405523,0.0003810001,0.0004093912,0.0002607186,0.0002234438,0.001191683,0.0003377142],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005084662,"about_ca_system_score_gemma":0.0006681675,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007338315,"about_ca_topic_score_gemma":0.003363999,"domain_scores_codex":[0.9994481,0.0003021876,0.00004235829,0.0000545018,0.00009181251,0.00006087402],"domain_scores_gemma":[0.9995739,0.0001429164,0.00006582565,0.00002684201,0.00002392055,0.0001665777],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6543684,0.01924323,0.009549884,0.002057489,0.001230305,0.0005537651,0.0001568542,0.002565604,0.03547886,0.0005233596,0.003482952,0.2707893],"study_design_scores_gemma":[0.2713073,0.6519191,0.03363343,0.0003513609,0.001117821,0.001057476,0.00008056068,0.002722603,0.009959498,0.0006393575,0.0271417,0.00006986483],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.97968,0.01231332,0.0005353899,0.0005290697,0.0007670687,0.001803888,0.0002723267,0.00005444322,0.004044598],"genre_scores_gemma":[0.9901909,0.004051545,0.00106029,0.000364738,0.000259887,0.001005831,0.0003986429,0.000006658977,0.0026615],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.003441659,"threshold_uncertainty_score":0.01151353,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04641934878625111,"score_gpt":0.3535923177234178,"score_spread":0.3071729689371667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}